9:00 a.m. - 9:55 a.m., Wednesday, October 9, 2013, Twin Peaks North/ South
With the sudden attention and spotlight on rare and ultra rare diseases, it seems everyone is forgetting about the once coveted blockbuster drug in the primary care setting and jumping on the orphan drug bandwagon. With patent cliffs looming, much of large biopharma has turned to niche indications but what does this mean for the primary market? We still need safer, more effective and less costly drugs for more common medical issues. What role can venture capital play in fostering the primary care disease market and what should emerging biotechs be thinking about?
- Charles C. Duncan, PhD, Managing Director & Senior Research Analyst, Piper Jaffray
- Marianne Andreach, VP of Strategic Marketing & Product Planning, Esperion Therapeutics
- Ed Mathers, Partner, New Enterprise Associates
- Michael Wyzga, President & CEO, Radius Health
Marianne Andreach is Vice President of Strategic Marketing and Product Planning. Prior to joining Esperion, Marianne was a consultant in the pharmaceutical industry. Previously, she was Senior Director, Business Development and Team Lead, MDCO-216 (ApoA-I Milano) at The Medicines Company. Marianne also worked in Medical Affairs at Pfizer Global R&D, and led Marketing and Product Planning at the original Esperion Therapeutics. Additionally, Marianne has worked in a variety of marketing and product planning roles at Bristol-Myers Squibb and Parke-Davis, including working on the launch teams for both Pravachol and Lipitor, as well as supporting both Plavix and Glucophage. Marianne earned a BA in Biology/History from the College of the Holy Cross.
Charles C. Duncan, PhD
Charles Duncan, Ph.D., joined Piper Jaffray in 2012 as a managing director and senior research analyst focused on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 17 years of sell-side experience during which he has covered a broad range of biopharma companies, most recently serving as an analyst at JMP Securities since 2002. Previously, Duncan covered the sector at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the Financial Times and StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis.
Duncan began his career as a manager of clinical development at Global Drug Development, Inc., a pharmaceutical development consulting firm, and he also launched InfusionVision Medical, a venture-backed start-up medical device company. He is a graduate of the University of Wisconsin-Madison and holds a doctorate in pharmaceutical sciences with a concentration in neuropharmacology from the University of Colorado.
Ed Mathers joined NEA as a Partner in August 2008 after spending 26 years working within the pharmaceutical/biotechnology industry in a variety of senior roles. Ed is focused on biotechnology and specialty pharmaceuticals investments, and is a director of Intarcia, Liquidia Technologies, Mirna Therapeutics, Ra Pharmaceuticals, and Rhythm Pharmaceuticals. Previously, Ed was a director of Plexxikon prior to its sale to Daiichi Sankyo. Ed is also a member of the Biotechnology Industry Organization (BIO) board, Southeast Bio board, and the NC State Physical and Mathematical Sciences Foundation board.
Immediately prior to joining NEA, Ed served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc., and was a director of MedImmune, LLC. In this role, he was a member of the leadership team that executed the sale of the company to Astra Zeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he served as Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems (now Nektar). Previously, Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.
Michael Wyzga is President and Chief Executive Officer, and a member of the Board of Directors, of Radius. Prior to joining Radius, he was Executive Vice President, Finance and Chief Financial Officer of Genzyme until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the firm's financial management worldwide. He provided strategic leadership in the successful $20.1 billion sale of Genzyme to Sanofi, the second-largest acquisition in biotechnology history. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.